CytomX Therapeutics (CTMX) Cash & Current Investments (2014 - 2026)

CytomX Therapeutics has reported Cash & Current Investments for 13 years, with the latest figure at $346.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 334.0% year-over-year to $346.7 million; the trailing twelve-month figure through Mar 2026 stood at $346.7 million (up 334.0% YoY), and the FY2025 full-year result was $137.1 million, up 36.2% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $346.7 million, up from $137.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $346.7 million in Q1 2026, with the low at $79.9 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $176.7 million across 5 years, with a median of $174.5 million in 2023.
• Annual changes were most pronounced in 2025 — Cash & Current Investments sank 46.84% — and 2026, when it soared 334.0%.
• CytomX Therapeutics' Cash & Current Investments stood at $193.6 million in 2022, then retreated by 9.88% to $174.5 million in 2023, then tumbled by 42.34% to $100.6 million in 2024, then surged by 36.2% to $137.1 million in 2025, then jumped by 152.97% to $346.7 million in 2026.
• The last three Cash & Current Investments figures came in at $346.7 million (Q1 2026), $137.1 million (Q4 2025), and $143.6 million (Q3 2025), per Business Quant data.